Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma

18 Feb 2022

Abstract excerpt

PURPOSE: Adoptive cell therapy (ACT) of tumor-infiltrating lymphocytes (TIL) historically yields a 40%-50% response rate in metastatic melanoma. However, the determinants of outcome are largely unknown. EXPERIMENTAL DESIGN: We investigated tumor-based genomic correlates of overall survival (OS), progression-free survival (PFS), and response to therapy by interrogating tumor samples initially collected to generate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Cutaneous Melanoma Detection and Management
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35190823
DOI: 10.1158/1078-0432.ccr-21-1060

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic MelanomaPMID 35190823Read ↗

Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy.Semantic proximity Read ↗

Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response RatesSemantic proximity Read ↗

Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patientsSemantic proximity Read ↗

Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma.Semantic proximity Read ↗

Genomic and Epigenomic Biomarkers of Immune Checkpoint Immunotherapy Response in Melanoma: Current and Future PerspectivesSemantic proximity Read ↗

Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanomaSemantic proximity Read ↗

CD4 Phenotypes Are Associated with Reduced Expansion of Tumor-Infiltrating Lymphocytes in Melanoma Patients Treated with Adoptive Cell Therapy.Semantic proximity Read ↗

The immune response-related genomic alterations in patients with malignant melanoma.Semantic proximity Read ↗

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaSemantic proximity Read ↗

Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanomaSemantic proximity Read ↗

Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanomaSemantic proximity Read ↗

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.